ArticleEnvironmental analysis, health and toxicology2025
Preclinical pharmacokinetics and tissue distribution of a polyhexamethylene guanidine derivative after ocular mucosal administration.
Article in Environmental analysis, health and toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic resistance is a critical medical issue. Antiseptics, which play a key role in treating and preventing eye infections and inflammations, have the potential to induce resistance in pathogenic microorganisms despite their broad antimicrobial spectrum. When introducing new active substances into ophthalmic treatments, it is crucial to assess the risk of side effects caused by the systemic action of the active compound. The succinic salt of polyhexamethylene guanidine derivative (ss-PHMGd) has shown high in vitro activity. This study aimed to evaluate the systemic effects of ss-PHMGd-based eye drops after ocular instillation in a preclinical model. Simple mathematical models were used to calculate pharmacokinetic parameters during instillation in two types of laboratory animals: guinea pigs and chinchilla rabbits. Groups received intravenous injections and ocular treatments. Tritium-labeled ss-PHMGd was used to quantify its concentration in organs and tissues. To test the linearity of the parameter relationships, data from three different doses were compared. Renal excretion was studied by quantifying ss-PHMGd concentrations in urine using radiometric methods. The results showed that ss-PHMGd-based eye drops present a low risk of systemic side effects and exhibit minimal penetration into other organs after instillation. No species-specific differences were found in the ADME parameters of the preclinical models (the guinea pig-to-chinchilla rabbit absorption ratio was 0.7). The AUC-D parameters exhibited a linear relationship for doses ranging from 0.5 of therapeutic dose (TD) to 5TD in guinea pigs. Renal excretion analysis revealed that 5.3% of the administered dose was excreted through the kidneys, indicating significant metabolic transformation or excretion via other pathways. This study enhances the understanding of the pharmacokinetics and safety of polyguanidines, with implications for toxicology and risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.